{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123274","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.593688+00:00","generated_at":"2026-05-30T03:42:50.445198+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Boundless Bio Q3 net loss $16.5M; cash $167.1M, runway into Q4 2026","bullets":["Net loss of $16.5M for Q3 2024 vs $13.2M in Q3 2023; R&D expenses $14.1M.","Cash, cash equivalents, and short-term investments total $167.1M as of Sept 30, 2024.","Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP trials; initial proof-of-concept data expected H2 2025.","Analytical validation for proprietary ecDNA diagnostic ECHO presented at ESMO September 2024.","G&A expenses $4.6M vs $3.3M year-over-year; general operating cash runway into Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123274","json":"https://secwatch.observer/filing/0000950170-24-123274.json","markdown":"https://secwatch.observer/filing/0000950170-24-123274.md","text":"https://secwatch.observer/filing/0000950170-24-123274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024123274/0000950170-24-123274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024123274/bold-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:42:50.445198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}